title: Consensus: the follow-up of the treated patient.
abstract: This is the first consensus document on the follow-up of the treated patient with non-small cell lung cancer that has been written by this group. The document has been drawn up by doctors coming from many different cultures and philosophical backgrounds. It acknowledges that there are published guidelines on the follow-up particularly those in trials, and does not wish to contradict these. There is lack of evidence-based medicine to recommend a strong general policy in this area. For those patients who were treated with curative intent the initial follow-up will depend upon the toxicity that is evident from the treatment given. Thereafter the interval between follow-up visits should be every 3 months for the first two years, then every 6 months for up to five years. Rapid and easy access to the multidisciplinary team should be available. Full examination and chest X-ray should be carried out on each visit but other investigations should be determined by clinical need. For those patients treated with palliative intent the interval between follow-up visits once the acute reactions have settled will depend upon the adequacy of the control of the symptom and the availability of separate palliative care teams. At all times the patient should have rapid access to the multidisciplinary team and in general frequent follow-up, that is at intervals of one to two months, may be appropriate during the first six months. Follow-up constitutes an important part of lung cancer management. Efforts should be made to gain clinical material to give us evidence-based guidelines.
authors.affiliation: Department of Radiotherapy, Mount Vernon Hospital, Northwood, Middlesex, UK. michele_saunders@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Saunders
authors.forename: J P
authors.initials: JP
authors.lastname: Sculier
authors.forename: D
authors.initials: D
authors.lastname: Ball
authors.forename: M
authors.initials: M
authors.lastname: Capello
authors.forename: K
authors.initials: K
authors.lastname: Furuse
authors.forename: P
authors.initials: P
authors.lastname: Goldstraw
authors.forename: A P
authors.initials: AP
authors.lastname: Meert
authors.forename: V
authors.initials: V
authors.lastname: Ninane
authors.forename: Y
authors.initials: Y
authors.lastname: Ohe
authors.forename: M
authors.initials: M
authors.lastname: Paesmans
authors.forename: K
authors.initials: K
authors.lastname: Park
authors.forename: R
authors.initials: R
authors.lastname: Pirker
authors.forename: P
authors.initials: P
authors.lastname: Postmus
authors.forename: Y
authors.initials: Y
authors.lastname: Sokolow
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung; D019317:Evidence-Based Medicine; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology* / Q000628:therapy; D008991:Monitoring, Physiologic; D010166:Palliative Care; D010347:Patient Care Planning; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D011379:Prognosis; D013902:Radiography, Thoracic; D012907:Smoking